Amgen Seeks to Buoy Tepezza with Injectable Data in Face of Incoming Competition
Amgen announced that its injectable formulation of Tepezza achieved its primary endpoint in a Phase 3 trial for thyroid eye disease (TED). The data suggest the drug can be administered subcutaneously, offering a more convenient alternative to the current intravenous infusion. The results arrive as Viridian Therapeutics unveiled its own Phase 3 outcomes for an oral TED therapy, intensifying competitive pressure. Amgen aims to leverage the injectable’s efficacy to solidify market leadership before the new entrant gains traction.
Many Teens Not Fully Vaccinated Against HPV Before Sexual Debut
New research published in JAMA Pediatrics shows that more than one‑fifth of adolescents in a Pennsylvania health system were either unvaccinated or incompletely vaccinated against HPV before becoming sexually active. While 79% completed the series before debut, 12% received no...
Machine Learning and Single-Cell Technology Combined to Drive High-Performance Cell Line Development
OneCyte and Kemp Proteins have formed a strategic partnership that fuses OneCyte’s high‑throughput single‑cell cloning platform with Kemp’s machine‑learning‑driven protein design system, PROTiQ. The combined workflow uses in‑silico sequence evaluation to flag developability risks, then rapidly screens thousands of clones...
Hologic CEO Steve MacMillan to Retire After Go-Private Deal
Hologic announced that CEO Steve MacMillan will retire as the company completes a Blackstone‑TPG go‑private transaction valued at $18.3 billion. The deal, which received all regulatory approvals, will close Tuesday and delist Hologic from Nasdaq, paying shareholders $76 per share plus...
Anthropic Pays $400M for Biotech; Praxis Epilepsy Drug Hits in Phase 1/2 Trial
San Francisco AI firm Anthropic announced a $400 million acquisition of stealth biotech Coefficient Bio, signaling its push into drug discovery. The purchase aims to integrate Anthropic’s large‑language‑model capabilities with biotech research pipelines. In parallel, Praxis Therapeutics disclosed encouraging Phase 1/2 data...
Takeda Ends Partnership with Denali Amid Restructuring
Takeda announced the termination of its eight‑year partnership with Denali Therapeutics, returning full rights to the experimental drug DNL593 ahead of its upcoming Phase I trial. The move is part of Takeda's broader restructuring aimed at streamlining its portfolio and...
Are Complete Dentures Right for You? Key Benefits Explained
The American Dental Association reports roughly 40.2 million U.S. adults are edentulous, underscoring a sizable market for tooth replacement. Modern complete dentures have evolved with digital scanning, computer‑aided design, and customized aesthetics, delivering better fit, comfort, and facial support. Immediate dentures...
Op-Ed | Dietary Guidelines for (Some) Americans: The Impact of Ignoring Health Equity in the DGA
The 2025‑2030 Dietary Guidelines for Americans (DGA) rejected 30 of the 56 recommendations from the Dietary Guidelines Advisory Committee (DGAC) after labeling the committee’s health‑equity focus as biased. Instead, the administration relied on a newly commissioned “Scientific Foundation” report that...
African Patients and Trialists Largely Left Out of CV Research
A new study reveals that African populations are dramatically underrepresented in cardiovascular clinical trials, with less than 4 % of 2,472 randomized controlled trials (RCTs) conducted exclusively in Africa and only 0.6 % appearing in top cardiology journals. Lead author Bamba Gaye...
5 Warning Signs of a Skull Fracture That May Turn Fatal
Skull fractures can become fatal if five key warning signs are missed: loss of consciousness, unequal pupils, worsening headache, fluid leaking from the nose or ears, and seizures. These symptoms indicate brain injury, bleeding, or increased intracranial pressure and require...
STAT+: Pharmalittle: We’re Reading About an FDA Delay Forcing a Biotech to Close, a Neurocrine Deal, and More
In February, Kezar Life Sciences secured an FDA agreement for a clinical trial on autoimmune hepatitis, but the meeting was cancelled four months late, prompting the biotech to begin winding down. Meanwhile, U.S. physicians are increasingly prescribing oral GLP‑1 weight‑loss...
Hypercortisolism Common in Patients with Resistant Hypertension
The MOMENTUM study of 1,086 patients with resistant hypertension found that 27.3% had endogenous hypercortisolism. Nearly a quarter of those positive cases displayed adrenal nodules, and 21.5% also had primary hyperaldosteronism, with 5.9% harboring both disorders. Hypercortisolism was associated with...
Key Takeaways From AACE’s 2026 Type 2 Diabetes Algorithm
American Association of Clinical Endocrinology (AACE) released its 2026 consensus algorithm for managing adult type 2 diabetes, the first revision since 2023. The update introduces a diagnostic classification chart to confirm type 2 diabetes and adds metabolic dysfunction‑associated steatotic liver disease (MASLD)...
Rethinking eCOA: Why Earlier Input by Data Managers Is Needed
Electronic clinical outcome assessment (eCOA) is a mature technology, yet its adoption lags behind other digital trial tools. The traditional siloed approach forces data managers to engage only after data collection, inflating costs and extending timelines. Involving data managers early...
Engineered Antibodies Pry Apart The Most Difficult Viruses
Researchers have engineered a bifunctional antibody fragment that simultaneously blocks Marburg virus attachment and neutralizes the exposed receptor‑binding site after the virus undergoes its conformational change. By mimicking the host cell receptor, the antibody tightly binds the viral protein, shutting...
Democratizing Innovation with Agentic AI
Microsoft’s new low‑code AI platform lets healthcare staff build custom agents without programming expertise, enabling rapid solutions for clinical and back‑office challenges. By offering drag‑and‑drop interfaces and pre‑built connectors to electronic health records and billing systems, the tool democratizes agentic...
Neurocrine to Acquire Prader-Will Drug in $2.9B Soleno Buyout
Neurocrine Biosciences agreed to acquire Soleno Therapeutics for $2.9 billion, securing the rare‑disease drug Vykat XR. Vykat generated $190 million in 2025 sales, including $92 million in the fourth quarter, but recent safety concerns and a slowdown in new patient starts have clouded its...
CuraTeQ Biologics Gets ‘Positive’ Results in Phase Study of Omalizumab
CuraTeQ Biologics, a subsidiary of Aurobindo Pharma, announced positive top‑line results from its Phase 3 trial of BP11, a biosimilar to omalizumab (Xolair). The study enrolled 608 patients across 80 sites in seven European countries and India, meeting all primary endpoints...
Ghent, Porto, Wroclaw: Future European HealthTech and MedTech Hubs
The European MedTech sector is entering a phase of industrial maturity, with the global market projected to grow from $549.5 billion in 2025 to $853.4 billion by 2035 at a 4.5% CAGR. Investment is concentrating in three emerging hubs—Ghent, Porto, and Wroclaw—each...
WELL Health Partners with AliveCor for Cardiac Monitoring in Canada
WELL Health announced a partnership with AliveCor to bring the Kardia mobile ECG platform to Canadian patients. The collaboration enables remote cardiac monitoring and real‑time cardiologist review through WELL Health’s telehealth network. By integrating AliveCor’s FDA‑cleared devices, the service aims...
How Multidisciplinary Care and Smarter Tools Can Transform MS Management: Steven Kheloussi, PharmD
Steven Kheloussi, PharmD, argues that smarter clinical decision‑support tools and multidisciplinary teams are essential for effective multiple sclerosis (MS) management. He highlights how integrated EHR‑embedded tools can consolidate relapse history, MRI data, and patient preferences to guide personalized therapy, while...
Complex Cataracts: Choosing the Right Fixation Technique
The article reviews current intraocular lens (IOL) fixation methods for complex cataract surgery, focusing on scleral‑sutured, Yamane‑type sutureless intrascleral, iris‑claw, and piggyback lenses. It highlights the Yamane technique’s advantages in reducing inflammation, eliminating suture‑related complications, and delivering stable centration. Iris‑claw...
When Algorithms Decide Visibility: Ben Beckley, CEO of RevHealth on the Future of Pharma
Ben Beckley, CEO of RevHealth, warns that AI is now the primary gateway to pharmaceutical information, turning search into zero‑click answer delivery. Pharma must move from traditional content publishing to engineering discoverability with machine‑readable, citation‑dense data that AI can surface...
From Data Ownership to Learning Velocity in Direct-to-Consumer Healthcare
Healthcare brands are shifting toward direct‑to‑consumer (DTC) engagement, expanding patient portals and digital front doors. Traditional commercialization stacks—data providers, manual intelligence, and media execution—remain siloed, limiting how quickly insights can be applied. While enterprises build internal data lakes and proprietary...
Not All Hospitals Have Equal Resources — Knowledge Sharing Can Help Level the Playing Field
Rural and children’s hospitals in the United States face severe financial strain, with 45% operating at a loss and more than 300 at risk of closing. The Centers for Medicare & Medicaid Services has launched the Rural Health Transformation program,...
STAT+: Stealth Biotech Stipple Bets on Secretive ADCs
Stealth biotech Stipple is quietly advancing secretive antibody‑drug conjugates (ADCs) as the market races toward targeted cancer therapies. A recent four‑month FDA review delay forced a cash‑strapped small biotech to shut down, underscoring the existential risk of regulatory setbacks for...
Advisors Should Keep an Eye on Healthcare Sector Amid Stronger-than-Expected Jobs Numbers
U.S. non‑farm payrolls rose by 178,000 in March, far exceeding expectations, while the unemployment rate held at 4.3%. The healthcare sector drove much of the gain, adding 76,000 jobs, with ambulatory services and physicians’ offices leading the surge. Healthcare stocks...
Workers’ Comp Provider Networks Cut Total Claim Costs by 26%, Drive Faster Access to Care
A Workers’ Compensation Research Institute study of over seven thousand lost‑time claims across 34 states finds that provider networks lower total claim costs by 26%, saving roughly $11,820 per claim at 36 months. Medical payments drop 27%, about $3,500 per...
Strategies for Hospices Supporting Family Caregivers
Family caregiving in the United States has surged to 63 million adults, a 45% increase since 2015, placing unprecedented strain on hospice providers. End‑of‑life caregivers average 20 hours of support per week, juggling medical, logistical, and emotional duties. Hospices are responding by...
Centene Latest Health Insurer To Shakeup Management Ranks
Centene announced creation of two senior executive roles, naming Daniel Finke as group president of markets and commercial and Michael Carson as group president of Medicare and specialty. The moves come as the insurer grapples with a $1 billion fourth‑quarter loss...
Media Networks Sydney Pty Limited - 687044 - 09/18/2024
The U.S. Food and Drug Administration issued a closeout letter to Media Networks Sydney Pty Ltd confirming that the company has discontinued its U.S. listings for Mylanta 2go Antacid Double Strength and Microlax Enema after corrective actions. The agency noted that...
Novel Approach to Clearing Brain Waste Shows Promise for Alzheimer's
Researchers have identified a novel method to boost the brain’s waste‑disposal system by targeting the DDR2 receptor, a protein previously studied for lung health. In mouse models, blocking DDR2 lowered amyloid‑beta production and enhanced clearance of toxic protein aggregates, leading...
Affinia Therapeutics Receives Approval From Health Canada to Initiate the UPBEAT© Trial, a Phase 1/2 Clinical Trial to Investigate AFTX-201...
Affinia Therapeutics has secured Health Canada approval to launch the UPBEAT© Phase 1/2 trial of its gene‑therapy candidate AFTX‑201 for BAG3‑associated dilated cardiomyopathy. The investigational product delivers a full‑length BAG3 transgene via a proprietary low‑dose AAV capsid, aiming for a one‑time...
Re: Men Need Fair Information About Screening for Prostate Cancer
A recent letter highlights how the European Randomized Study of Screening for Prostate Cancer’s 23‑year data are being misread. The trial showed one prostate cancer death prevented for every 456 men invited to PSA screening, but the accompanying statistic of...
Neurocrine Will Pay $2.9B for Soleno and Its Prader-Willi Medicine
Neurocrine BioSciences announced a $2.9 billion acquisition of Soleno Therapeutics, paying $53 per share for the rare‑disease specialist. The deal brings Soleno’s late‑stage Prader‑Willi syndrome therapy into Neurocrine’s growing portfolio. Soleno, a profitable company, adds a commercial platform and additional rare‑disease...
Join Us Tomorrow: How Capitol Imaging Is Using AI-Enabled RIS, Scheduling Bots and Smart Staffing Strategies to Take Care of...
Capitol Imaging Services, a 60‑location outpatient imaging network in the Gulf South and Southeast, is piloting an AI‑enabled radiology information system (RIS) to automate front‑office tasks. Partnering with AbbaDox, the group uses an AI voice agent named Abby to parse...
Neurocrine Expands Into Metabolic Diseases with $2.9 Billion Soleno Buyout
Neurocrine Biosciences announced a $2.9 billion cash acquisition of Soleno Therapeutics, marking its first foray into metabolic diseases. The deal secures Vykat XR, the inaugural FDA‑approved treatment for hyperphagia in Prader‑Willi syndrome, expanding Neurocrine’s rare‑disease portfolio. Soleno shareholders receive $53 per share,...
:max_bytes(150000):strip_icc():format(jpeg)/nursinghome-MorsaImages-96fe38d35fbf4156bac7c27f3c10bb31.jpg)
$10,000 a Month for Long-Term Care Is Becoming the Norm—What That Means for Families
Long‑term care costs in U.S. nursing homes have risen to an average of about $10,000 per month in 2026, with prices ranging from $5,800 in low‑cost states to over $32,000 in high‑cost markets like Alaska. Medicare only pays for the...
Stipple Bio Launches with $100M to Find More Precise Targets on Cancer Proteins
Stipple Bio, founded by cancer biologists Aaron Ring and colleagues, announced its launch with a $100 million Series A round. The company’s mission is to pinpoint highly precise binding sites on cancer‑related proteins, steering clear of oversaturated targets like PD‑1×VEGF or HER2....
Parkinson’s Awareness Month 2026: Alpha Synuclein Emerges as Leading Target in Disease Pipeline
During Parkinson’s Awareness Month 2026, GlobalData reports a clear shift in the drug development landscape toward alpha‑synuclein as the top therapeutic target. While 53% of the 64 approved Parkinson’s drugs still focus on dopamine receptors, the pipeline now includes 62...
China's Syneron Raises $150M for Peptides, Adding to Last Year's $100M
Chinese biotech Syneron Bio announced a $150 million Series B financing round, bringing its total capital raised to $250 million after a $100 million round last year. The funds will be allocated to advance its peptide therapeutic platform, a drug...
1.6 Million Teens Are Vaping. Health Risks Are Worse Than You Think
A recent Forbes analysis highlights that 1.6 million American teens—about 5.9% of middle and high school students—are currently using e‑cigarettes, marking a decline from the 2019 peak but revealing a surge in daily vaping intensity. Daily nicotine vaping among youth rose...
Novo Nordisk: Downgrading To 'Sell' As GLP-1 Pipeline Faces Many Risks
Novo Nordisk was downgraded from Buy to Sell as its GLP‑1 pipeline encounters multiple headwinds. The CagriSema obesity candidate failed to prove non‑inferior weight loss against Eli Lilly’s tirzepatide in the REDEFINE‑4 trial, dampening pipeline momentum. Meanwhile, the oral Wegovy launch is...
Study: Toxic Exposure in Pregnancy May Drive Disease Risk Across Generations
A Washington State University study found that a single exposure to the fungicide vinclozolin during pregnancy can trigger disease patterns that persist for up to 20 generations in rats. The epigenetic alterations in germline cells act like stable mutations, with...
OPM Leans Into 'Well Care' As It Reshapes Federal Health Plans for 2027
The Office of Personnel Management (OPM) unveiled its 2027 Federal Employees Health Benefits (FEHB) agenda, branding it “well care” to broaden focus on physical and mental wellness. Key mandates include free access to all CDC‑recommended vaccines, required coverage of at...
The Antibiotic Trap
India’s antibiotics are cheap, ubiquitous and often sold in half‑doses by street‑side pharmacies to workers who cannot afford missed wages. Weak regulatory oversight, rampant use in livestock and massive pharmaceutical‑plant waste have created a perfect storm for antimicrobial resistance (AMR)....
Emergency Jabs After 100 Children Die of Suspected Measles in a Month in Bangladesh
Bangladesh has launched an emergency measles‑rubella vaccination drive after more than 100 child deaths and over 7,500 suspected cases since mid‑March. The outbreak, the deadliest in recent memory, exposed gaps in routine immunisation and a missed special campaign since 2020....
Nine Pilot Programs Lead the Charge in Behavioral Health Data Interoperability
The Office of the National Coordinator for Health IT (ONC) and SAMHSA launched the $20 million Behavioral Health Information Technology (BHIT) Initiative to tackle persistent interoperability gaps in behavioral health. In February 2026, nine pilot programs across nine states received awards ranging...
Scotland Pilots Newborn Screening for Spinal Muscular Atrophy
Scotland has launched a two‑year pilot to add spinal muscular atrophy (SMA) to its routine newborn heel‑prick screening, becoming the first UK nation to do so. The program targets the roughly three to four infants born with SMA each year,...
Perks Persuade Participants
Clinical trial sponsors are shifting from cash and checks to reloadable incentive cards to streamline participant compensation. Reloadable cards function like debit cards, allowing multiple reloads, real‑time tracking, and universal acceptance. InComm InCentives' Participant Perks Card offers a Visa‑branded, white‑label...